Armata Pharmaceuticals Files 8-K

Ticker: ARMP · Form: 8-K · Filed: Sep 11, 2025 · CIK: 921114

Armata Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyArmata Pharmaceuticals, INC. (ARMP)
Form Type8-K
Filed DateSep 11, 2025
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: regulation-fd, disclosure

Related Tickers: ARMP

TL;DR

Armata Pharma (ARMP) filed an 8-K on 9/10/25. Standard disclosure, no major news yet.

AI Summary

Armata Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, to report under Regulation FD. The filing indicates the company's common stock trades under the symbol ARMP on the NYSE American exchange. No specific material events or financial details beyond the reporting requirement were detailed in this particular filing.

Why It Matters

This filing serves as a public notification of material information, ensuring transparency for investors regarding Armata Pharmaceuticals, Inc.'s regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure under Regulation FD and does not contain new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Armata Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report under Regulation FD, ensuring timely public disclosure of any material information.

On what date is the earliest event reported in this filing?

The earliest event reported in this filing is dated September 10, 2025.

What is the trading symbol for Armata Pharmaceuticals, Inc.'s common stock?

The trading symbol for Armata Pharmaceuticals, Inc.'s common stock is ARMP.

On which exchange is Armata Pharmaceuticals, Inc.'s common stock registered?

Armata Pharmaceuticals, Inc.'s common stock is registered on the NYSE American.

Does this 8-K filing detail specific financial results or material business developments?

This specific 8-K filing, under Item 7.01 Regulation FD Disclosure, does not detail specific financial results or material business developments beyond its reporting function.

Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2025-09-10 18:15:35

Filing Documents

01

Item 7.01 Regulation FD Disclosure. The Company posted a corporate presentation dated September 10, 2025 (the "H.C. Wainwright Presentation"), which is furnished as Exhibit 99.1 hereto, to its website at https://investor.armatapharma.com/image/Armata_+2025_HCW_Conference_+Sept_10_2025.pdf . The H.C. Wainwright Presentation was delivered by Dr. Deborah Birx, M.D., the Company's Chief Executive Officer, at the H.C. Wainwright 27th Annual Global Investment Conference held on September 10, 2025. The information contained in the H.C. Wainwright Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, except as may be required by the federal securities laws, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the Company disclaims any inferences regarding the materiality of such information that may arise as a result of it furnishing such information under

01 of this Current Report on Form 8-K

Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 H.C. Wainwright Presentation dated September 10, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). - 2 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2025 Armata Pharmaceuticals, Inc. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing